Response Biomedical (RPBIF) 0.8070 $RPBIF
Response Biomedical Corp. Announces Closing of First Tranche of Private Placement
Marketwire Canada - Fri Jun 17, 6:33PM CDT
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jun 17, 2016) - Response Biomedical Corp. ("Response" or the "Company"
(TSX:RBM)(OTC:RPBIF) announces the closing of the first tranche of the non-brokered private placement (the "Private Placement" previously announced by the Company on May 30, 2016. In its press release of June 16, 2016, the Company announced that it has entered into subscription agreements for up to 1,785,716 common shares at a price of U.S.$0.56 per share for total gross proceeds of approximately U.S.$1,000,000 in the Private Placement. Under the first tranche of the Private Placement, OrbiMed Advisors LLC ("OrbiMed", an investment management firm focused on the healthcare sector and the Company's largest shareholder, acquired 892,858 common shares for total gross proceeds to the Company of approximately U.S.$500,000. The second tranche of the Private Placement from Shanghai Runda Medical Technology Co., Ltd is expected to close in due course subject to certain regulatory approvals in China being received.
RBM.TO: 1.08 (+0.01)
Response Biomedical Corp. Enters into Definitive Agreements for Going-Private Transaction and Private Placement
Marketwired - Thu Jun 16, 2:32AM CDT
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jun 16, 2016) - Response Biomedical Corp. ("Response" or the "Company" (TSX:RBM)(OTC:RPBIF) announces that it has entered into a definitive arrangement agreement (the "Arrangement Agreement" with 1077801 B.C. Ltd., a company owned by OrbiMed Asia Partners, LP, OrbiMed Private Investments III, LP and OrbiMed Associates III, LP and Shanghai Runda Medical Technology Co., Ltd. ("Runda" pursuant to which 1077801 B.C. Ltd. will acquire all of the issued and outstanding common shares of Response ("Response Shares" for cash consideration of $1.12 per Response Share (except in the case of certain rollover shareholders who will instead receive shares of 1077801 B.C. Ltd. on a 1 for 1 basis) (the "Transaction" by way of a statutory plan of arrangement under the Business Corporations Act (British Columbia) (the "Arrangement". The cash consideration price represents a 51% premium to the closing price of the Response Shares on the Toronto Stock Exchange ("TSX" on June 15, 2016, the date prior to the date of signing of the Arrangement Agreement. OrbiMed Advisors LLC ("OrbiMed", an investment management firm focused on the healthcare sector, and its affiliates currently own 4,970,543 Response Shares, representing 50.1% of the issued and outstanding Response Shares, based on 9,925,256 Response Shares outstanding.
RBM.TO: 1.08 (+0.01)
TSX Delisting Review - Response Biomedical Corp. (Symbol: RBM)
CNW Group - Tue May 31, 7:30AM CDT
DELISTING REVIEW Response Biomedical Corp. (the "Company" - Further to TSX Bulletin 2016-0389 dated April 18, 2016, TSX has decided to extend its review of the eligibility of the common shares (Symbol: RBM) of the Company for continued listing for a period of 30 days.
RBM.TO: 1.08 (+0.01), X.TO: 60.05 (-0.12)
Response Biomedical Corp. Announces Intention to Enter Into Private Placement
Marketwire Canada - Mon May 30, 7:01AM CDT
VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 30, 2016) - Response Biomedical Corp. ("Response" or the "Company" (TSX:RBM)(OTC:RPBIF) announces it intends to enter into a private placement (the "Private Placement" of common shares of the Company for gross proceeds of up to U.S.$1,000,000.
RBM.TO: 1.08 (+0.01)
Response Biomedical Corp. Announces First Quarter 2016 Financial Results
Marketwire Canada - Mon May 16, 4:02PM CDT
VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 16, 2016) - Response Biomedical Corp. ("Response" or the "Company" (TSX:RBM)(OTC:RPBIF), a commercial stage in-vitro medical device company with products for the laboratory and point of care markets, today reported financial results for its first quarter ended March 31, 2016, including a 2016 GAAP net loss of $(1.3 million), or $(0.13) per share, compared with a GAAP net loss of $(1.1 million), or $(0.11) per share in 2015, and 2016 negative Adjusted EBITDA (a non-GAAP financial measure) of $(321,000), compared with a negative Adjusted EBITDA of $(655,000) in 2015.
RBM.TO: 1.08 (+0.01)
Response Biomedical Corp. Awarded Capital Equipment Supplier Contract by Vizient, Inc.
Marketwired - Thu Apr 07, 4:26PM CDT
Response Biomedical Corp. ("Response" or the "Company" (TSX: RBM) (OTC: RPBIF), a commercial stage in-vitro medical device company with products for the laboratory and point of care markets, today reported that it has been awarded a three-year Capital Equipment Supplier Contract with Vizient, Inc. for Response's cardiovascular and infectious disease product lines.
RBM.TO: 1.08 (+0.01)
Response Biomedical Corp. Announces Fourth Quarter and Fiscal 2015 Financial Results
Marketwired - Mon Mar 21, 4:03PM CDT
Response Biomedical Corp. ("Response" or the "Company" (TSX: RBM)(OTC: RPBIF) a commercial stage in-vitro medical device company with products for the laboratory and point of care markets, today reported financial results for its fourth quarter and year ended December 31, 2015, including a 2015 GAAP net loss of $(150,000), or $(0.02) per share, compared with a GAAP net loss of $(2.1 million), or $(0.26) per share in 2014, and 2015 Adjusted EBITDA (a non-GAAP financial measure) of $822,000, compared with a negative Adjusted EBITDA of $(4.0 million) in 2014.
RBM.TO: 1.08 (+0.01)
Response Biomedical Receives Health Canada Approval and CE Mark for the RAMP(R) Procalcitonin Test for Sepsis
Marketwired - Mon Jan 11, 4:00PM CST
Response Biomedical Corp. ("Response" or "the Company" (TSX: RBM)(OTCQB: RPBIF), has received Health Canada approval and CE Mark for a new RAMP(r) diagnostic test that measures the levels of Procalcitonin ("PCT". PCT is a biomarker elevated in the blood of patients suffering from sepsis, also known as blood poisoning. Physicians today use PCT to distinguish bacterial sepsis from other causes of similar symptoms(1,2). The RAMP(r) Procalcitonin test is a rapid diagnostic assay that provides quantitative results in 15 minutes directly from a small blood sample.
RBM.TO: 1.08 (+0.01)
Response Biomedical Receives Health Canada Approval and CE Mark for the RAMP® Procalcitonin Test for Sepsis
Marketwire Canada - Mon Jan 11, 4:00PM CST
Response Biomedical Corp. ("Response" or "the Company" (TSX:RBM)(OTCQB:RPBIF), has received Health Canada approval and CE Mark for a new RAMP(r) diagnostic test that measures the levels of Procalcitonin ("PCT". PCT is a biomarker elevated in the blood of patients suffering from sepsis, also known as blood poisoning. Physicians today use PCT to distinguish bacterial sepsis from other causes of similar symptoms(1,2). The RAMP(r) Procalcitonin test is a rapid diagnostic assay that provides quantitative results in 15 minutes directly from a small blood sample.
RBM.TO: 1.08 (+0.01)
Response Biomedical Corp. Announces Receipt of Fifth Milestone in Co-Development Collaboration
Marketwired - Wed Dec 30, 4:03PM CST
Response Biomedical Corp. ("Response" or "the Company" (TSX: RBM)(OTCQB: RPBIF), has received the fifth milestone of US$720,000 in the Collaboration Agreement with Hangzhou Joinstar Biomedical Technology Co. Ltd. ("Joinstar". The milestone payment was received upon the receipt of certain testing reports for the high throughput rapid immunoassay analyzer developed by Joinstar. On February 16th, 2015 the companies entered into definitive Collaboration and Supply Agreements whereby Response and Joinstar will co-develop components and assays for the new analyzer and Response will provide certain materials to Joinstar required for Joinstar to manufacture and sell these assays specifically to run on their new analyzer.
RBM.TO: 1.08 (+0.01)
Response Biomedical Announces Strategic Alliances in Japan with Alere Medical and Long Time Partner Shionogi
GlobeNewswire - Tue Dec 08, 4:00PM CST
Response Biomedical Corp. ("Response" or "the Company" (TSX:RBM) (OTCQB:RPBIF), a commercial stage in-vitro diagnostics company with products for the laboratory and point of care markets, today reported a restructuring of the marketing of its BNP (B-type natriuretic peptide) products in Japan. Effective January 5, 2016, Alere Medical Co., Ltd. ("Alere Japan" will become the exclusive national distributor in Japan for the marketing and sales of Response manufactured BNP tests and readers. Response's long time partner in Japan, Shionogi & Co. Ltd ("Shionogi", will continue to supply biological reagents to Response under separate license and supply agreements.
RBM.TO: 1.08 (+0.01)
Response Biomedical Corp. Announces Notification of TSX Continued Listing Review
GlobeNewswire - Thu Nov 19, 4:35AM CST
Response Biomedical Corp. ("Response" or "the Company" (TSX:RBM) (OTCQB:RPBIF), a commercial stage in-vitro medical device company with products for the laboratory and point of care markets, today announced that it has received notice that the Toronto Stock Exchange (the "TSX" is reviewing the eligibility for continued listing on the TSX of the common shares of Response pursuant to Part VII of the TSX Company Manual. The TSX initiated its review because the price of Response's shares have traded below $0.68 for 30 consecutive trading days, and as a result, the market value of the publicly-held common shares (as defined by the TSX) did not meet the minimum threshold of $2 million required under the TSX rules. Under the TSX definition, shares held by certain significant shareholders and the Company's directors and officers, which in the case of Response total approximately 70% of its outstanding shares, are excluded from the calculation of publicly-held shares. The Company has been granted 120 days in which to demonstrate compliance with the continued listing requirements of the TSX, pursuant to the TSX's Remedial Review Process. Receipt of this notice has no immediate effect on the listing of the Company's shares.
RBM.TO: 1.08 (+0.01)
Response Biomedical Corp. Announces Third Quarter 2015 Financial Results
GlobeNewswire - Thu Nov 12, 7:43PM CST
Response Biomedical Corp. ("Response" or "the Company" (TSX:RBM) (OTCQB:RPBIF) a commercial stage in-vitro medical device company with products for the laboratory and point of care markets, today reported financial results for its third quarter and nine months ended September 30, 2015. Third quarter highlights include a 60% increase in total revenue, a 10% increase in product sales, a GAAP net income of $729,000, and a positive Adjusted EBITDA of $311,000.
RBM.TO: 1.08 (+0.01)
Response Biomedical Corp. Announces Receipt of Fourth Milestone in Co-Development Collaboration
Marketwired - Tue Sep 08, 7:02AM CDT
Response Biomedical Corp. ("Response" or "the Company" (TSX: RBM)(OTCQB: RPBIF) today announced that it has received the fourth milestone of US$648,000 in the Collaboration Agreement with Hangzhou Joinstar Biomedical Technology Co. Ltd. ("Joinstar". The milestone payment was received upon the delivery of certain materials for the high throughput rapid immunoassay analyzer developed by Joinstar. On February 16th, 2015 the companies entered into definitive Collaboration and Supply Agreements whereby Response and Joinstar will co-develop components and assays for the new analyzer and Response will provide certain materials to Joinstar required for Joinstar to manufacture and sell these assays specifically to run on their new analyzer.
RBM.TO: 1.08 (+0.01)
Response Biomedical Corp. Announces Second Quarter 2015 Financial Results
Marketwire Canada - Fri Aug 14, 4:00PM CDT
Response Biomedical Corp. ("Response" or "the Company" (TSX:RBM)(OTCQB:RPBIF) today reported financial results for its second quarter and six months ended June 30, 2015 including a 39% increase in total revenue, a 16% increase in product sales, positive Adjusted EBITDA of $631,000, and a GAAP net loss of $2,000.
RBM.TO: 1.08 (+0.01)
Response Biomedical Corp. Announces Closing of First Tranche of Private Placement
Marketwire Canada - Fri Jun 17, 6:33PM CDT
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jun 17, 2016) - Response Biomedical Corp. ("Response" or the "Company"
(TSX:RBM)(OTC:RPBIF) announces the closing of the first tranche of the non-brokered private placement (the "Private Placement" previously announced by the Company on May 30, 2016. In its press release of June 16, 2016, the Company announced that it has entered into subscription agreements for up to 1,785,716 common shares at a price of U.S.$0.56 per share for total gross proceeds of approximately U.S.$1,000,000 in the Private Placement. Under the first tranche of the Private Placement, OrbiMed Advisors LLC ("OrbiMed", an investment management firm focused on the healthcare sector and the Company's largest shareholder, acquired 892,858 common shares for total gross proceeds to the Company of approximately U.S.$500,000. The second tranche of the Private Placement from Shanghai Runda Medical Technology Co., Ltd is expected to close in due course subject to certain regulatory approvals in China being received. RBM.TO: 1.08 (+0.01)
Response Biomedical Corp. Enters into Definitive Agreements for Going-Private Transaction and Private Placement
Marketwired - Thu Jun 16, 2:32AM CDT
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jun 16, 2016) - Response Biomedical Corp. ("Response" or the "Company"
(TSX:RBM)(OTC:RPBIF) announces that it has entered into a definitive arrangement agreement (the "Arrangement Agreement" with 1077801 B.C. Ltd., a company owned by OrbiMed Asia Partners, LP, OrbiMed Private Investments III, LP and OrbiMed Associates III, LP and Shanghai Runda Medical Technology Co., Ltd. ("Runda" pursuant to which 1077801 B.C. Ltd. will acquire all of the issued and outstanding common shares of Response ("Response Shares" for cash consideration of $1.12 per Response Share (except in the case of certain rollover shareholders who will instead receive shares of 1077801 B.C. Ltd. on a 1 for 1 basis) (the "Transaction" by way of a statutory plan of arrangement under the Business Corporations Act (British Columbia) (the "Arrangement". The cash consideration price represents a 51% premium to the closing price of the Response Shares on the Toronto Stock Exchange ("TSX" on June 15, 2016, the date prior to the date of signing of the Arrangement Agreement. OrbiMed Advisors LLC ("OrbiMed", an investment management firm focused on the healthcare sector, and its affiliates currently own 4,970,543 Response Shares, representing 50.1% of the issued and outstanding Response Shares, based on 9,925,256 Response Shares outstanding. RBM.TO: 1.08 (+0.01)
TSX Delisting Review - Response Biomedical Corp. (Symbol: RBM)
CNW Group - Tue May 31, 7:30AM CDT
DELISTING REVIEW Response Biomedical Corp. (the "Company"
- Further to TSX Bulletin 2016-0389 dated April 18, 2016, TSX has decided to extend its review of the eligibility of the common shares (Symbol: RBM) of the Company for continued listing for a period of 30 days. RBM.TO: 1.08 (+0.01), X.TO: 60.05 (-0.12)
Response Biomedical Corp. Announces Intention to Enter Into Private Placement
Marketwire Canada - Mon May 30, 7:01AM CDT
VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 30, 2016) - Response Biomedical Corp. ("Response" or the "Company"
(TSX:RBM)(OTC:RPBIF) announces it intends to enter into a private placement (the "Private Placement" of common shares of the Company for gross proceeds of up to U.S.$1,000,000. RBM.TO: 1.08 (+0.01)
Response Biomedical Corp. Announces First Quarter 2016 Financial Results
Marketwire Canada - Mon May 16, 4:02PM CDT
VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 16, 2016) - Response Biomedical Corp. ("Response" or the "Company"
(TSX:RBM)(OTC:RPBIF), a commercial stage in-vitro medical device company with products for the laboratory and point of care markets, today reported financial results for its first quarter ended March 31, 2016, including a 2016 GAAP net loss of $(1.3 million), or $(0.13) per share, compared with a GAAP net loss of $(1.1 million), or $(0.11) per share in 2015, and 2016 negative Adjusted EBITDA (a non-GAAP financial measure) of $(321,000), compared with a negative Adjusted EBITDA of $(655,000) in 2015. RBM.TO: 1.08 (+0.01)
Response Biomedical Corp. Awarded Capital Equipment Supplier Contract by Vizient, Inc.
Marketwired - Thu Apr 07, 4:26PM CDT
Response Biomedical Corp. ("Response" or the "Company"
(TSX: RBM) (OTC: RPBIF), a commercial stage in-vitro medical device company with products for the laboratory and point of care markets, today reported that it has been awarded a three-year Capital Equipment Supplier Contract with Vizient, Inc. for Response's cardiovascular and infectious disease product lines. RBM.TO: 1.08 (+0.01)
Response Biomedical Corp. Announces Fourth Quarter and Fiscal 2015 Financial Results
Marketwired - Mon Mar 21, 4:03PM CDT
Response Biomedical Corp. ("Response" or the "Company"
(TSX: RBM)(OTC: RPBIF) a commercial stage in-vitro medical device company with products for the laboratory and point of care markets, today reported financial results for its fourth quarter and year ended December 31, 2015, including a 2015 GAAP net loss of $(150,000), or $(0.02) per share, compared with a GAAP net loss of $(2.1 million), or $(0.26) per share in 2014, and 2015 Adjusted EBITDA (a non-GAAP financial measure) of $822,000, compared with a negative Adjusted EBITDA of $(4.0 million) in 2014. RBM.TO: 1.08 (+0.01)
Response Biomedical Receives Health Canada Approval and CE Mark for the RAMP(R) Procalcitonin Test for Sepsis
Marketwired - Mon Jan 11, 4:00PM CST
Response Biomedical Corp. ("Response" or "the Company"
(TSX: RBM)(OTCQB: RPBIF), has received Health Canada approval and CE Mark for a new RAMP(r) diagnostic test that measures the levels of Procalcitonin ("PCT". PCT is a biomarker elevated in the blood of patients suffering from sepsis, also known as blood poisoning. Physicians today use PCT to distinguish bacterial sepsis from other causes of similar symptoms(1,2). The RAMP(r) Procalcitonin test is a rapid diagnostic assay that provides quantitative results in 15 minutes directly from a small blood sample. RBM.TO: 1.08 (+0.01)
Response Biomedical Receives Health Canada Approval and CE Mark for the RAMP® Procalcitonin Test for Sepsis
Marketwire Canada - Mon Jan 11, 4:00PM CST
Response Biomedical Corp. ("Response" or "the Company"
(TSX:RBM)(OTCQB:RPBIF), has received Health Canada approval and CE Mark for a new RAMP(r) diagnostic test that measures the levels of Procalcitonin ("PCT". PCT is a biomarker elevated in the blood of patients suffering from sepsis, also known as blood poisoning. Physicians today use PCT to distinguish bacterial sepsis from other causes of similar symptoms(1,2). The RAMP(r) Procalcitonin test is a rapid diagnostic assay that provides quantitative results in 15 minutes directly from a small blood sample. RBM.TO: 1.08 (+0.01)
Response Biomedical Corp. Announces Receipt of Fifth Milestone in Co-Development Collaboration
Marketwired - Wed Dec 30, 4:03PM CST
Response Biomedical Corp. ("Response" or "the Company"
(TSX: RBM)(OTCQB: RPBIF), has received the fifth milestone of US$720,000 in the Collaboration Agreement with Hangzhou Joinstar Biomedical Technology Co. Ltd. ("Joinstar". The milestone payment was received upon the receipt of certain testing reports for the high throughput rapid immunoassay analyzer developed by Joinstar. On February 16th, 2015 the companies entered into definitive Collaboration and Supply Agreements whereby Response and Joinstar will co-develop components and assays for the new analyzer and Response will provide certain materials to Joinstar required for Joinstar to manufacture and sell these assays specifically to run on their new analyzer. RBM.TO: 1.08 (+0.01)
Response Biomedical Announces Strategic Alliances in Japan with Alere Medical and Long Time Partner Shionogi
GlobeNewswire - Tue Dec 08, 4:00PM CST
Response Biomedical Corp. ("Response" or "the Company"
(TSX:RBM) (OTCQB:RPBIF), a commercial stage in-vitro diagnostics company with products for the laboratory and point of care markets, today reported a restructuring of the marketing of its BNP (B-type natriuretic peptide) products in Japan. Effective January 5, 2016, Alere Medical Co., Ltd. ("Alere Japan" will become the exclusive national distributor in Japan for the marketing and sales of Response manufactured BNP tests and readers. Response's long time partner in Japan, Shionogi & Co. Ltd ("Shionogi", will continue to supply biological reagents to Response under separate license and supply agreements. RBM.TO: 1.08 (+0.01)
Response Biomedical Corp. Announces Notification of TSX Continued Listing Review
GlobeNewswire - Thu Nov 19, 4:35AM CST
Response Biomedical Corp. ("Response" or "the Company"
(TSX:RBM) (OTCQB:RPBIF), a commercial stage in-vitro medical device company with products for the laboratory and point of care markets, today announced that it has received notice that the Toronto Stock Exchange (the "TSX" is reviewing the eligibility for continued listing on the TSX of the common shares of Response pursuant to Part VII of the TSX Company Manual. The TSX initiated its review because the price of Response's shares have traded below $0.68 for 30 consecutive trading days, and as a result, the market value of the publicly-held common shares (as defined by the TSX) did not meet the minimum threshold of $2 million required under the TSX rules. Under the TSX definition, shares held by certain significant shareholders and the Company's directors and officers, which in the case of Response total approximately 70% of its outstanding shares, are excluded from the calculation of publicly-held shares. The Company has been granted 120 days in which to demonstrate compliance with the continued listing requirements of the TSX, pursuant to the TSX's Remedial Review Process. Receipt of this notice has no immediate effect on the listing of the Company's shares. RBM.TO: 1.08 (+0.01)
Response Biomedical Corp. Announces Third Quarter 2015 Financial Results
GlobeNewswire - Thu Nov 12, 7:43PM CST
Response Biomedical Corp. ("Response" or "the Company"
(TSX:RBM) (OTCQB:RPBIF) a commercial stage in-vitro medical device company with products for the laboratory and point of care markets, today reported financial results for its third quarter and nine months ended September 30, 2015. Third quarter highlights include a 60% increase in total revenue, a 10% increase in product sales, a GAAP net income of $729,000, and a positive Adjusted EBITDA of $311,000. RBM.TO: 1.08 (+0.01)
Response Biomedical Corp. Announces Receipt of Fourth Milestone in Co-Development Collaboration
Marketwired - Tue Sep 08, 7:02AM CDT
Response Biomedical Corp. ("Response" or "the Company"
(TSX: RBM)(OTCQB: RPBIF) today announced that it has received the fourth milestone of US$648,000 in the Collaboration Agreement with Hangzhou Joinstar Biomedical Technology Co. Ltd. ("Joinstar". The milestone payment was received upon the delivery of certain materials for the high throughput rapid immunoassay analyzer developed by Joinstar. On February 16th, 2015 the companies entered into definitive Collaboration and Supply Agreements whereby Response and Joinstar will co-develop components and assays for the new analyzer and Response will provide certain materials to Joinstar required for Joinstar to manufacture and sell these assays specifically to run on their new analyzer. RBM.TO: 1.08 (+0.01)
Response Biomedical Corp. Announces Second Quarter 2015 Financial Results
Marketwire Canada - Fri Aug 14, 4:00PM CDT
Response Biomedical Corp. ("Response" or "the Company"
(TSX:RBM)(OTCQB:RPBIF) today reported financial results for its second quarter and six months ended June 30, 2015 including a 39% increase in total revenue, a 16% increase in product sales, positive Adjusted EBITDA of $631,000, and a GAAP net loss of $2,000. RBM.TO: 1.08 (+0.01)
